AK Sabharwal, SP Bajaj, A Ameri, SM Tricomi, TM Hyers, TE Dahms, FB Taylor Jr and MS Bajaj
Department of Medicine, St. Louis University School of Medicine, Missouri.

Tissue factor pathway inhibitor (TFPI) is an anticoagulant protein primarily synthesized by the endothelium. A major fraction (approximately 85%) of TFPI remains associated with the endothelium, whereas a small fraction (approximately 15%) is secreted into the blood. In our attempts to search for a marker(s) of endothelial injury in the setting of adult respiratory distress syndrome (ARDS), we retrospectively measured plasma TFPI levels in patients at risk for and with ARDS caused by several etiologic factors. Plasma von Willebrand factor antigen (vWF-Ag), another endothelial-specific protein, was also measured in these patients. The mean plasma TFPI levels were slightly elevated (approximately 1.3-fold), whereas vWF-Ag levels were significantly elevated (approximately 3-fold) in the at-risk group as compared with those in the normal subjects. Both the TFPI (approximately 1.8-fold) and the vWF-Ag (approximately 4-fold) levels were further elevated in the ARDS group. Moreover, the sequential plasma samples from patients with ARDS had progressively increased levels of vWF-Ag and TFPI up to Days 4 and 8, respectively. Neither plasma vWF-Ag nor TFPI levels correlated with mortality in the at-risk group or the ARDS group. TFPI levels were also measured in bronchoalveolar lavage fluids (BALF). The levels (ng/ml) were: normal subjects, 0.05 +/- 0.02 SE; at-risk group, 0.35 +/- 0.16 SE; ARDS group, 0.99 +/- 0.28 SE. Thus, the BALF TFPI levels were increased approximately 7-fold in the at-risk group and approximately 20-fold in the ARDS group relative to the value in the normal subjects. These findings indicate increased local synthesis of TFPI in the alveolar space both in the at-risk patients and in those with ARDS. In additional studies in a primate model of sepsis, lethal doses (LD100) of E. coli administered to baboons resulted in a progressive increase in TFPI levels (approximately 2-fold at 6 h), whereas sublethal doses caused only minimal increase (approximately 1.2-fold). The vWF-Ag levels were elevated approximately 5-fold after infusion of LD100 concentrations of E. coli at 6 h and 4-fold after infusion of sublethal concentrations of E. coli at 24 h. Autopsies on animals in the LD100 group revealed pulmonary congestion, leukocyte infiltration, edema, and hemorrhage, all suggestive of acute lung injury. Thus, in the setting of acute lung injury plasma vWF-Ag appears to be considerably increased prior to significant damage to the endothelium, whereas increased plasma TFPI occurs only after severe injury.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				J. A. Bastarache, L. Wang, Z. Wang, K. H. Albertine, M. A. Matthay, and L. B. Ware Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L874 - L881. [Abstract] [Full Text] [PDF]

				H. Tang, L. Ivanciu, N. Popescu, G. Peer, E. Hack, C. Lupu, F. B. Taylor Jr, and F. Lupu Sepsis-Induced Coagulation in the Baboon Lung Is Associated with Decreased Tissue Factor Pathway Inhibitor Am. J. Pathol., September 1, 2007; 171(3): 1066 - 1077. [Abstract] [Full Text] [PDF]

				L. B. Ware, M. D. Eisner, B. T. Thompson, P. E. Parsons, and M. A. Matthay Significance of Von Willebrand Factor in Septic and Nonseptic Patients with Acute Lung Injury Am. J. Respir. Crit. Care Med., October 1, 2004; 170(7): 766 - 772. [Abstract] [Full Text] [PDF]

				A. D. Betensley and J. R. Yankaskas Factor viia for alveolar hemorrhage in microscopic polyangiitis Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1291 - 1292. [Full Text] [PDF]

				S. IDELL Anticoagulants for Acute Respiratory Distress Syndrome . Can They Work? Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 517 - 520. [Full Text] [PDF]

				E. de Jonge, P. E. P. Dekkers, A. A. Creasey, C. E. Hack, S. K. Paulson, A. Karim, J. Kesecioglu, M. Levi, S. J. H. van Deventer, and T. van der Poll Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia Blood, February 15, 2000; 95(4): 1124 - 1129. [Abstract] [Full Text] [PDF]

				A. K. C. Chan, L. Berry, L. Mitchell, B. Baranowski, H. O'Brodovich, and M. Andrew Effect of a novel covalent antithrombin-heparin complex on thrombin generation on fetal distal lung epithelium Am J Physiol Lung Cell Mol Physiol, June 1, 1998; 274(6): L914 - L921. [Abstract] [Full Text] [PDF]

				C. T. Park, A. A. Creasey, and S. D. Wright Tissue Factor Pathway Inhibitor Blocks Cellular Effects of Endotoxin by Binding to Endotoxin and Interfering With Transfer to CD14 Blood, June 15, 1997; 89(12): 4268 - 4274. [Abstract] [Full Text] [PDF]